Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 20/9/2018
SIETES contiene 92559 citas

 
 
 1 a 20 de 343 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita originalTiene citas relacionadas Cita con resumen
Wallach JD, Ross JS. Gabapentin approvals, off-label use, and lessons for postmarketing evaluation efforts. JAMA 2018;319:27 de febrero. [Ref.ID 102781]
2.Enlace a cita original Cita con resumen
Qato DM, Ozenberger K, Olfson M. Prevalence of prescription medications with depression as a potential adverse effect among adults in the United States. JAMA 2018;319:12 de junio. [Ref.ID 102780]
3.Enlace a cita originalTiene citas relacionadas Cita con resumen
Moore A, Derry S, Wiffen P. Gabapentin for chronic neuropathic pain. JAMA 2018;319:27 de febrero. [Ref.ID 102777]
4. Cita con resumen
Enke O, New HA, New CH, Mathieson S, McLachlan AJ, Latimer J, Maher CG, Lin CC. Anticonvulsants in the treatment of low back pain and lumbar radicular pain: a systematic review and meta-analysis. Can Med Assoc J 2018;190:E786-93. [Ref.ID 102754]
6.Enlace a cita original Cita con resumen
Throckmorton DC, Gottlieb S, Woodcock J. The FDA and the next wave of drug abuse — Proactive pharmacovigilance. N Engl J Med 2018;379:19 de julio. [Ref.ID 102679]
8.Enlace a cita original Cita con resumen
Johansen ME. Gabapentinoid use in the United States 2002 trhrough 2015. JAMA Intern Med 2018;178:febrero. [Ref.ID 102530]
9. Cita con resumen
Bjørk M, Riedel B, Spiqset O, Veiby G, Kolstad E, Daltveit AK, Gilhus NE. Association of folic acid supplementation during pregnancy with the risk of autistic traits in children exposed to antiepileptic drugs In utero. JAMA Neurology 2017:26 de diciembre. [Ref.ID 102193]
10. Cita con resumen
Peckham AM, Fairman KA, Sclar DA. Call for increased pharmacovigilance of gabapentin. BMJ 2017;359:j5456. [Ref.ID 102156]
11. Cita con resumen
Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W. Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case–control study. PLOS Medicine 2017:3 de octubre. [Ref.ID 102112]
12. Cita con resumen
Pinto RZ, Verwoerd AJH, Koes BW. Which pain medications are effective for sciatica (radicular leg pain)?. BMJ 2017;359:j4248. [Ref.ID 102095]
13. Cita con resumen
Ho JM-W, Macdonald EM, Luo J, Gomes T, Antoniou T, Mamdani MM, Juurlink DN. Pregabalin and heart failure: A population-based study. Pharmacoepidemiol Drug Saf 2017;26:1087-92. [Ref.ID 102064]
14. Cita con resumen
Buttram ME, Kurtz SP, Dart RC, Margolin ZR. Law enforcement-derived data on gabapentin diversion and misuse, 2002-2015: diversion rates and qualitative research findings. Pharmacoepidemiol Drug Saf 2017;26:1083-7. [Ref.ID 102063]
15. Cita con resumen
Zaccara G, Giovannelli F, Giorgi FS, Franco V, Gasparini S, Tacconi FM. Do antiepileptic drugs increase the risk of infectious diseases? A meta-analysis of placebo-controlled studies. Br J Clin Pharmacol 2017;83:1873-9. [Ref.ID 102027]
17. Cita con resumen
Zaccara G, Giovannelli F, Giorgi FS, Franco V, Gasparini S, Benedetto U. Tolerability of new antiepileptic drugs: a network meta-analysis. Eur J Clin Pharmacol 2017;73:811-7. [Ref.ID 101994]
18.Tiene citas relacionadas Cita con resumen
19. Cita con resumen
Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]
20. Cita con resumen
Anónimo. Daclizumab for MS. Drug Ther Bull 2017;55:18-21. [Ref.ID 101403]
Seleccionar todas
 
 1 a 20 de 343 siguiente >>